Immunodiagnostic Systems Dividends - IDH

Immunodiagnostic Systems Dividends - IDH

Best deals to access real time data!
Monthly Subscription
for only
Level 2 Basic
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Immunodiagnostic Systems Holdings Plc IDH London Ordinary Share GB00B01YZ052 ORD 2P
  Price Change Price Change % Stock Price High Price Low Price Open Price Close Price Last Trade
  -5.00 -1.72% 285.00 290.00 285.00 290.00 290.00 13:44:52
more quote information »
Industry Sector

Immunodiagnostic Systems IDH Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount

Top Dividend Posts

longshanks: A big hike in the share price on negligible volume... LEAK!!
junior21: Yes, very welcome finish to the week. My concern is that the share price is getting ahead of itself and results may disappoint in comparison. This may lead to a pull back at some point, though I expect it would be short lived based on the recent price action.
123prezzie: Can anyone comment in the fall in the share price which seems to correlate with the departure of Dr Wittek (non-exec) from the Board? This is a negelected thread considering the useful increase in share price. I came in at 290 after the big drop - should I be exiting?
major clanger: Investec has downgraded its recommendation on medical diagnostic product manufacturer Immunodiagnostic Systems [LON:IDH] to 'hold' from 'buy' after the company published an in-line set of preliminary results, believing the shares will pause for breath after the recent strong run. The shares have increased in value by 40 per cent since the beginning of the year. The City broker has increased its price target to 460 pence per share (up from 360 pence). Separately, N+1 Singer has reaffirmed its 'buy' rating and 395 pence price target, while Canaccord Genuity has stuck with its 'hold' call leaving its price target unchanged at 404 pence per share. At 10:09am: Immunodiagnostic Systems share price was unchanged at 447.5 pence. (Courtesy of
123prezzie: Spacecake Old products always die off faster than management anticipates and new ones take longer to grow. Trading is profitable, cash flow is positive and there is cash in the bank. The share price got pushed too high and disappointment had the usual effect of walloping the price. It will take time to restore confidence and there may be a bid in the meantime. If there is, let us hope that it is a trade buyer paying full wack, not private equity cutting management in on the deal and talking the price down. As I said in an earlier post, I have followed this company for some years but didn't buy until the price came down to sensible levels this year. I am now happy to sit tight.
mw16: Stegrego True. But the company has 5 times the turnover and profit and have said they will return to profit growth in 2013. This year will see turnover up but a slight decrease in profit margin. All in all no reason for the share price to fall 75%. I think you will find this share price will recover strongly. I have put my money where my mouth is.
mw16: 2007 the companys share price was in this range. Turnover 9.92m retained profit 1.59m 2012 Turnover 52m profit 14.5m Do you not think we have value here? Outlooks are just that. See the figures above, these are reality.
masurenguy: A more bullish view today from LCF Research. I've no position in IDH but now on my watchlist after the large fall in price over the past 6 months. Letter from the Editor Ben Graham is considered to be the first proponent of value investing and has been credited by Warren Buffett as being a major influence on his investment approach. Graham observed that: "In the short term, the stockmarket behaves like a voting machine, but in the long term it acts like a weighing machine. In the long term, true value will be reflected in the stock price. The investor is best off concentrating on the real life performance of his companies and receiving dividends, rather than being too concerned with Mr Market's often irrational behaviour." The share price performance in recent months of Immunodiagnostics Systems Holdings, in which I have a holding, is a good illustration both of the above observations and also of the opportunities thrown up for private investors who choose to invest with the mindset of long term owners. It also illustrates the inherent weaknesses of the UK's capital markets processes in supporting the development of the sort of Mittelsand companies which the UK economy so badly needs. Here are some salient features: The share price has moved from 800p (mkt cap £225m) in August 2010 to a high of 1218p (mkt cap £345m) in August 2011 to a price of 291.5p (mkt cap of £82.6m) on 23rd January 2012. The price drop in Autumn 2011 was occasioned by the impact of increased competition in the Vitamin D market. The company had told the market during the previous year that increased competition would occur and had also, in my opinion, outlined a sound strategy for mitigating over the medium term the effects of increasing competition. A former senior investment banker tells me that as the market cap rose to its high in August 2011, it passed certain trigger points which brought in new institutional investors. However, as the market cap fell, it triggered the need to sell on the part of those investors. As readers will know, my views on the ability of the marketmaking system to provide a stabilising influence under such circumstances are unprintable! In my opinion the company did not articulate its strategy for being a growth stock as clearly as it could have done at the time of its November 2011 interim results announcement. The commercial reality of developing a long term business does not always occur as a straight line process, fitting neatly into accounting periods, which makes it essential to communicate strategy very succinctly particularly when trading is challenging. Looking at the company's track record since listing on AIM in 2004, it has demonstrated the ability to identify some excellent strategic acquisitions and to be able to execute on challenging projects embracing science, engineering and markets. These skills do not evaporate over night. I and several investors whom I know who have a Ben Graham mindset are currently increasing our IDS shareholdings. It is a style of investing which is akin to a salvage tug patiently waiting for the valuable 'wrecks' which Mr Market insists upon delivering from time to time! Charles Breese: Editor
silverfern: alf, no Dave Evans knows exactly what he is doing. I mean, job done, the new set of skills needed when a company needs to get into a market through innovation and acquisition is different from the set that keeps them there. REplacing the one with the other is not easy. IDH shares have been hit but it's their fault- they give scant info in their RNS's in the good times and enjoyed 1000% share price rises in two years so if the Board have options and shares its now for them to decide to 'fess up in a mature way or take the AIM way and restrict info and wing it. WOrks on the way up but it really doesn't if you stall
pentangle: Not currently a holder, but I would not necessarily say that a warning is coming. IDH share price action mirrors many other small caps currently, where bad news has neither appeared nor seems imminent. May well be market led not IDH led.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191021 13:29:30